Stryker (NYSE:SYK) had its price target lifted by SunTrust Banks to $205.00 in a report published on Monday, February 4th, The Fly reports. SunTrust Banks currently has a positive rating on the medical technology company’s stock. SunTrust Banks also issued estimates for Stryker’s Q1 2019 earnings at $1.84 EPS, Q2 2019 earnings at $1.96 EPS, Q3 2019 earnings at $1.90 EPS, Q4 2019 earnings at $2.44 EPS, FY2019 earnings at $8.15 EPS, FY2020 earnings at $8.89 EPS and FY2021 earnings at $9.69 EPS.
A number of other equities research analysts have also recently commented on the company. Credit Suisse Group upgraded Stryker to an outperform rating in a research report on Thursday, January 31st. Oppenheimer set a $170.00 price target on shares of Stryker and gave the stock a hold rating in a research report on Friday, November 9th. Citigroup decreased their price objective on Stryker from $174.00 to $169.00 and set a neutral rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research restated a hold rating and issued a $162.00 price objective on shares of Stryker in a research report on Monday, December 31st. Finally, UBS Group initiated coverage on Stryker in a report on Tuesday, November 27th. They issued a neutral rating and a $180.00 price target for the company. Seven research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $186.26.
SYK traded up $3.07 during trading on Monday, hitting $191.58. The company’s stock had a trading volume of 1,344,179 shares, compared to its average volume of 1,583,128. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.41 and a current ratio of 2.02. Stryker has a twelve month low of $144.75 and a twelve month high of $191.84. The firm has a market cap of $70.31 billion, a PE ratio of 26.21, a price-to-earnings-growth ratio of 2.32 and a beta of 0.86.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, beating the consensus estimate of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The firm had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Research analysts predict that Stryker will post 8.13 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a dividend yield of 1.09%. Stryker’s dividend payout ratio is currently 28.45%.
In other Stryker news, VP Bijoy Sagar sold 2,361 shares of the stock in a transaction on Friday, December 7th. The stock was sold at an average price of $171.24, for a total transaction of $404,297.64. Following the transaction, the vice president now owns 2,361 shares in the company, valued at approximately $404,297.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Damon Hutchinson sold 15,995 shares of the stock in a transaction on Friday, February 8th. The stock was sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. In the last three months, insiders sold 47,925 shares of company stock valued at $8,384,790. 7.30% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in shares of Stryker by 6.3% in the fourth quarter. FMR LLC now owns 5,934,622 shares of the medical technology company’s stock worth $930,251,000 after purchasing an additional 353,028 shares during the period. Actinver Wealth Management Inc. bought a new position in shares of Stryker in the fourth quarter worth $305,000. Aspire Private Capital LLC bought a new position in shares of Stryker in the fourth quarter worth $77,000. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Stryker in the fourth quarter worth $963,000. Finally, WealthTrust Fairport LLC boosted its stake in shares of Stryker by 0.9% during the fourth quarter. WealthTrust Fairport LLC now owns 61,759 shares of the medical technology company’s stock valued at $9,681,000 after purchasing an additional 548 shares in the last quarter. Hedge funds and other institutional investors own 74.26% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: How liquidity affects the bid-ask spread
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.